Kineta Shares Are Trading Higher After the Company Announced That It Entered Into an Exclusivity and Right of First Offer Agreement With TuHURA Biosciences to Grant the Immune-oncology Company Exclusive Rights to Acquire Its Anti-VISTA Antibody.
Kineta Shares Are Trading Higher After the Company Announced That It Entered Into an Exclusivity and Right of First Offer Agreement With TuHURA Biosciences to Grant the Immune-oncology Company Exclusive Rights to Acquire Its Anti-VISTA Antibody.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.